...
首页> 外文期刊>Hepato-gastroenterology. >Survival differences between Milan criteria after down-staging and De novo Milan in living donor liver transplantation for hepatocellular carcinoma.
【24h】

Survival differences between Milan criteria after down-staging and De novo Milan in living donor liver transplantation for hepatocellular carcinoma.

机译:米兰标准在肝细胞癌肝脏移植肝癌中的米兰标准与De Novo Milan之间的生存差异。

获取原文
获取原文并翻译 | 示例
           

摘要

This study reports our experiences of adult living donor liver transplantation (LDLT) corresponding to downstaging.Between July 1992 and April 2008, we performed 553 adult LDLTs (35.1%, 553/1575) for HCC. Sixty-five patients was not treated before LDLT and belonged to Milan criteria, classified as De novo Milan group (De novo-M); 22 HCC patients did not meet Milan criteria initially, but subsequently met the criteria after downstaging, classified as artificial Milan group (Artificial-M). The evaluation of downstaging was based on preoperative CT scan and explanted liver biopsy, and excluded the patients having unclear treatment history on analysis.Artificial-M showed significantly less Child C patients (25%) than De novo-M (64.5%) (0.037). Artificial-M had greater tumor burden than De novo-M in maximal tumor size (2.5 +/- 1.2 versus 2.2 +/- 0.95 cm), sum of tumor diameter (3.4 +/- 1.4 versus 2.4 +/- 1.0 cm), number of nodules (1.8 +/- 0.9 versus 1.2 +/- 0.5), respectively. Five-year cumulative survival was not different between Artificial-M and De novo-M (83.9% versus 93.9%), but 5-year disease free survival were significantly different (71.1% versus 96.5%) (p = 0.0016).Five year overall survival rates after LDLT were good in both groups. However, stricter follow-up is necessary in Artificial-M considering greater tumor burden and higher recurrence rate compared to De novo-M.
机译:本研究报告了我们对应于下山的成人生活供体肝移植(LDLT)的经验。1992年7月和2008年4月,我们进行了553名成年LDLTS(35.1%,553/1575)。在LDLT之前没有治疗六十五名患者,属于米兰标准,被归类为De Novo Milan Group(de Novo-M); 22个HCC患者最初没有满足米兰标准,但随后达到下行后的标准,分类为人工米兰组(人造M)。下瓣的评价是基于术前CT扫描和外植检的肝脏活组织检查,并排除了治疗史上未清除的患者。人工M表现出明显减少的儿童C患者(25%),而不是Novo-M(64.5%)(0.037 )。人工-M在最大肿瘤大小(2.5 +/- 1.2对2.2 +/- 0.95厘米)中具有更大的肿瘤负荷(2.5 +/- 1.2,肿瘤直径和3.4 +/- 1.4与2.4 +/- 1.0厘米),结节数(1.8 +/- 0.9与1.2 +/- 0.5)。人工m和de novo-m之间的五年累积存活率(83.9%对93.9%),但5年的无病生存率显着差异(71.1%,与96.5%)(p = 0.0016).Five年在这两个群体中LDLT良好后的整体存活率。然而,与De Novo-M相比,在人造-M中,在人造-M中需要更严格的随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号